Australian Clinical Labs Ltd
ASX:ACL
Cash Flow Statement
Cash Flow Statement
Australian Clinical Labs Ltd
| Jun-2021 | Dec-2021 | Jun-2022 | Dec-2022 | Jun-2023 | Dec-2023 | Jun-2024 | Dec-2024 | Jun-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||
| Stock-Based Compensation |
1
|
0
|
1
|
0
|
2
|
0
|
3
|
0
|
3
|
|
| Cash Taxes Paid |
(19)
|
(24)
|
(69)
|
(71)
|
(18)
|
(3)
|
(10)
|
(16)
|
(14)
|
|
| Cash Interest Paid |
(39)
|
(16)
|
(11)
|
(12)
|
(14)
|
(16)
|
(17)
|
(18)
|
(18)
|
|
| Change in Working Capital |
0
|
0
|
0
|
0
|
0
|
0
|
1
|
0
|
0
|
|
| Cash from Operating Activities |
154
N/A
|
228
+48%
|
284
+24%
|
165
-42%
|
144
-13%
|
154
+7%
|
160
+4%
|
167
+5%
|
183
+9%
|
|
| Investing Cash Flow | ||||||||||
| Capital Expenditures |
(10)
|
(14)
|
(21)
|
(17)
|
(7)
|
(7)
|
(7)
|
(7)
|
(8)
|
|
| Other Items |
3
|
(57)
|
(51)
|
10
|
(5)
|
(12)
|
(1)
|
7
|
(0)
|
|
| Cash from Investing Activities |
(6)
N/A
|
(71)
-1 069%
|
(72)
-1%
|
(7)
+90%
|
(12)
-69%
|
(20)
-61%
|
(7)
+63%
|
(0)
+98%
|
(9)
-7 914%
|
|
| Financing Cash Flow | ||||||||||
| Net Issuance of Common Stock |
146
|
141
|
(5)
|
(1)
|
(1)
|
0
|
(2)
|
(6)
|
(19)
|
|
| Net Issuance of Debt |
(36)
|
(257)
|
(192)
|
(81)
|
(40)
|
(97)
|
(124)
|
(141)
|
(135)
|
|
| Cash Paid for Dividends |
(42)
|
(21)
|
(24)
|
(107)
|
(97)
|
(28)
|
(20)
|
(24)
|
(25)
|
|
| Other |
(216)
|
(8)
|
(0)
|
(0)
|
0
|
(0)
|
(0)
|
(0)
|
0
|
|
| Cash from Financing Activities |
(147)
N/A
|
(145)
+2%
|
(221)
-52%
|
(189)
+14%
|
(138)
+27%
|
(125)
+9%
|
(146)
-16%
|
(171)
-17%
|
(179)
-4%
|
|
| Change in Cash | ||||||||||
| Effect of Foreign Exchange Rates |
(0)
|
0
|
0
|
0
|
(0)
|
(0)
|
(0)
|
0
|
0
|
|
| Net Change in Cash |
0
N/A
|
12
+3 103%
|
(9)
N/A
|
(31)
-252%
|
(6)
+79%
|
9
N/A
|
6
-30%
|
(4)
N/A
|
(5)
-14%
|
|
| Free Cash Flow | ||||||||||
| Free Cash Flow |
144
N/A
|
214
+48%
|
263
+23%
|
148
-44%
|
137
-8%
|
147
+7%
|
153
+4%
|
160
+5%
|
174
+9%
|
|